AUS
NZ
UK
CA
USA
IND
Healthcare
Insider Confidence in AdAlta (ASX:1AD) Sparks ASX Buzz
November 27, 2025 07:21 PM AEDT| By Team Kalkine MediaAdAlta (ASX:1AD) has caught attention due to increased insider involvement over the past year. This long-form article explores why insider ownership matters, what recent actions may signal about the company’s direction, and how the broader
Proteomics International: Cash Use & Growth Strategy (ASX:PIQ)
November 27, 2025 06:29 PM AEDT| By Team Kalkine MediaThis article explores the cash usage and expansion strategies of Proteomics International Laboratories (ASX:PIQ), offering a clear look at how the biotechnology company navigates its funding needs while advancing research within Australia’s healthcar...
Unlocking Insights on CSL Ltd (ASX:CSL) Share Performance
November 27, 2025 05:43 PM AEDT| By Team Kalkine MediaExplore how CSL Ltd (ASX:CSL) continues to demonstrate steady growth in the ASX stock market, with a strong operational framework, revenue trends, and financial stability that make it a notable company for investors watching ASX dividend stocks.
Mesoblast (ASX:MSB) Outlook: Ryoncil Sales & Trial Update
November 27, 2025 05:38 PM AEDT| By Team Kalkine MediaExplore Mesoblast (ASX:MSB) valuation insights as Ryoncil revenue guidance and pivotal clinical trials spark market attention. Understand its market position, pipeline developments, and valuation context within the ASX stock market.
Imugene & JW Therapeutics Partner on CF33-CD19 for Tumors
November 27, 2025 04:47 PM AEDT| By Team Kalkine MediaImugene (ASX:IMU) partners with JW Therapeutics to explore CF33-CD19 in combination with CD19 Car-T therapy for solid tumors, highlighting a novel "mark and kill" approach and advancing oncology innovation on the ASX stock market.
Breakthrough Immunotherapy in Focus: Imugene (ASX:IMU) on ASX 200
November 27, 2025 04:02 PM AEDT| By SamImugene partners with JW Therapeutics to expand CAR-T therapy into solid tumours, aiming to transform oncology treatment with innovative virus-cell combination strategies impacting the ASX 200.
Recce Pharmaceuticals Expands IP Footprint in Hong Kong ASX 200 Update
November 27, 2025 03:58 PM AEDT| By SamRecce Pharmaceuticals (ASX:RCE) secures Hong Kong patent, advancing R327 and R529 anti-infectives with ongoing Phase 3 trials and expanded Asian IP footprint.
Proteomics International (ASX:PIQ) Cash Flow Overview
November 27, 2025 12:19 PM AEDT| By Team Kalkine MediaExplore how Proteomics International Laboratories (ASX:PIQ) manages its cash burn while investing in growth. Understand its cash runway, funding options, and operational resilience within the ASX stock market landscape.
Is Imricor Medical Systems (ASX:IMR) Navigating Debt Wisely?
November 27, 2025 12:06 PM AEDT| By Team Kalkine MediaThis article explores the financial health of Imricor Medical Systems (ASX:IMR), focusing on its debt management, balance sheet strength, and growth outlook. It explains how the company’s current resources position it in the ASX stock market and what...
AdAlta (ASX:1AD) Insider Activity Shows Growing Confidence in Company Outlook
November 27, 2025 11:58 AM AEDT| By Team Kalkine MediaAdAlta (ASX:1AD) insiders have shown renewed confidence through increased shareholding, reflecting their commitment to the company’s long-term growth. Insider activity highlights trust in strategic direction despite market challenges.
Star Combo Pharma (ASX:S66): Key Business Moves Worth Watching
November 27, 2025 11:48 AM AEDT| By Team Kalkine MediaStar Combo Pharma (ASX:S66) is showing steady growth in earnings and revenue, supported by strong insider ownership and sound governance. This article explores its financial performance, market position, and why it remains an interesting company to m...
Race Oncology Advances R&D for Cancer Therapy Progress (ASX:RAC)
November 27, 2025 11:26 AM AEDT| By Team Kalkine MediaRace Oncology (ASX:RAC) receives a significant R&D tax refund under the Federal Government’s innovation program, strengthening efforts to advance its RC two twenty therapy and supporting the initiation of its lung cancer trial in Australia.
Why Pro Medicus (ASX:PME) Stands Strong in the Healthcare Technology Race
November 26, 2025 08:32 PM AEDT| By Team Kalkine MediaAn in-depth look at Pro Medicus Ltd and what makes its radiology software business a notable name within healthcare technology on the ASX. The article explores industry drivers, revenue resilience, ethical investor focus.
Race Oncology Lung Cancer Trial Update: ASX 200 Spotlight
November 26, 2025 07:32 PM AEDT| By SamRace Oncology (ASX:RAC) begins HARNESS-1 lung cancer trial, exploring RC220 and osimertinib in EGFR-mutated NSCLC with ctDNA patient screening.
Nebulised R327 Shows Strong Pneumonia Response: ASX 200 Treatment Insights
November 26, 2025 06:59 PM AEDT| By SamInhaled R327 research highlights the expanding influence of synthetic anti-infective science in Australia, reinforcing interest in respiratory therapies, hospital-focused delivery systems and evolving infection-control pathways.
Recce Pharma’s Inhaled R327 Advances Drug-Resistant Pneumonia
November 26, 2025 06:30 PM AEDT| By Team Kalkine MediaRecce Pharmaceuticals (ASX:RCE) reports strong preclinical results for inhaled R327 against multidrug-resistant pneumonia, highlighting innovative delivery and broad-spectrum activity.
4DMedical Ltd Quotation Sparks ASX 200 Market Interest
November 26, 2025 05:50 PM AEDT| By Sam4DMedical Ltd lists new securities on ASX, enhancing its market presence, driving sector engagement, and influencing ASX 200 activity across medical technology and investor-focused segments.
Race Oncology Gains Ethics Nod for Lung Cancer RC220 Study
November 26, 2025 05:36 PM AEDT| By Team Kalkine MediaRace Oncology (ASX:RAC) has received ethical approval to progress its RC220 treatment into an early-stage study for a specific type of lung cancer. This article explores how the therapy will be tested,
Pro Medicus Stock Insights: ASX 200 Performance & Market Trends
November 26, 2025 03:35 PM AEDT| By SamPro Medicus (ASX:PME) shows strong growth through US contracts and healthcare innovation, remaining resilient in a volatile ASX 200 and highlighting technology sector potential in Australia.
SECTOR SURGE: ASX Momentum Builds Amid Inflation Heat
November 26, 2025 03:03 PM AEDT| By SamThe market rose steadily despite inflation pressure, supported by healthcare strength, sustainable agriculture interest, resource exploration progress and innovative energy developments. Sector interplay offered a balanced tone across the session.
Advertise your brand on Kalkine Media